Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP
Ellie Kelepouris, MD, FACP, FAHA
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Javed Butler, MD, MPH, MBA
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Patrick Rossignol, MD, PhD
Future Directions in Managing Hyperkalemia in CKD and HF
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Potassium Binders: Safety Comes First!
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD
Sydney Tang, MBBS, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar Desai, MD
Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
Implementing the SOC Induction Therapies in AAV
Managing Patients With AAV in the Rheumatology Clinic
Andreas Kronbichler, MD
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.